IQV Aug 2023 185.000 put
| Previous close | 5.33 |
| Open | 5.33 |
| Bid | 3.30 |
| Ask | 3.80 |
| Strike | 185.00 |
| Expiry date | 2023-08-18 |
| Day's range | 5.33 - 5.33 |
| Contract range | N/A |
| Volume | |
| Open interest | 389 |
Motley FoolIs Veeva Systems a Buy Now?
The stock is trading at a high multiple despite revenue that's growing by mid-single-digit percentages.
- Business Wire
IQVIA & (RED) Announce Groundbreaking Partnership to Support Laboratory System Strengthening
RESEARCH TRIANGLE PARK, N.C., May 25, 2023--IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life science industry, announced a groundbreaking partnership today with (RED), the organization co-founded by Bono and Bobby Shriver to fight AIDS and the injustices that enable pandemics to thrive, to support laboratory system strengthening and save lives.
- Business Wire
Global Oncology R&D Activity Remains High and More Patients Have Been Treated for Cancer, says IQVIA Institute for Human Data Science
RESEARCH TRIANGLE PARK, N.C., May 24, 2023--Global research and development activity in oncology remained at historically high levels in 2022, up 22% from 2018, and the global number of patients treated with approved medicines increased at an average of 5% annually over the same period, according to a new report from the IQVIA Institute for Human Data Science on Global Oncology Trends 2023. Over the last five years, a total of 115 novel active substances in oncology have launched globally; simul
ZacksIQVIA's (IQV) Extensive Database Blocks New Entrants
A strong database of patient records and a huge market are tailwinds for IQVIA's (IQV) success.
- Business Wire
IQVIA Announces Pricing of Upsized Offering of Senior Secured Notes and Senior Notes
INNOVATION PARK, N.C., May 18, 2023--IQVIA Holdings Inc. (NYSE:IQV) today announced that its wholly-owned subsidiary, IQVIA Inc. (the "Issuer"), priced an offering of $1,250,000,000 in aggregate principal amount of senior notes, which was upsized due to strong demand, consisting of $750,000,000 in aggregate principal amount of senior secured notes due 2028 (the "Senior Secured Notes") and $500,000,000 in aggregate principal amount of senior notes due 2030 (the "Senior Notes" and, together with t
- Business Wire
IQVIA Announces Offering of Senior Secured Notes and Senior Notes
INNOVATION PARK, N.C., May 18, 2023--IQVIA Holdings Inc. (NYSE:IQV) today announced that its wholly-owned subsidiary, IQVIA Inc. (the "Issuer"), intends to raise $1,000,000,000 through an offering of senior secured notes due 2028 and senior notes due 2030 (collectively, the "Notes").
- Business Wire
IQVIA Celebrates Sheetal Telang, Winner of Healthcare Businesswoman's Association Rising Star Award
RESEARCH TRIANGLE PARK, N.C., May 11, 2023--IQVIA (NYSE:IQV) today announced that Sheetal Telang, vice president of Therapeutic Strategy, has been honored with the 2023 Rising Star award by the Healthcare Businesswoman's Association (HBA).
ZacksZacks Industry Outlook Highlights Trane Technologies, IQVIA Holdings and TuSimple Holdings
Trane Technologies, IQVIA Holdings and TuSimple Holdings are part of the Zacks Industry Outlook article.
Zacks3 Stocks to Watch From a Promising Technology Services Industry
The Zacks Technology Services industry seeks to benefit from increased digitization and dependency on technology, and the growing adoption of the multi-cloud model. TT, IQV and TSP are well-positioned to witness a demand surge.
- Business Wire
Use of Medicines in the U.S. Continued to Grow in 2022 while Patient Out-of-Pocket Costs Remain Low, Says IQVIA Institute
RESEARCH TRIANGLE PARK, N.C., May 02, 2023--The U.S. market for medicines grew by 5% in 2022, reaching a total value of $429Bn on a net price basis. This was driven by a range of factors, including an increase in health services utilization, which is now back to pre-pandemic levels, and the entry of new medicines into the market. Balancing these drivers of growth, was a lack of net price increases for branded drugs and patient out-of-pocket costs per retail prescription remaining under $10. This
ZacksIQVIA Holdings (IQV) Surpasses Q1 Earnings & Revenue Estimates
IQVIA Holdings (IQV) first-quarter 2023 revenues improve year over year.
ZacksIQVIA Holdings (IQV) Tops Q1 Earnings and Revenue Estimates
IQVIA (IQV) delivered earnings and revenue surprises of 1.66% and 1.21%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
IQVIA Reports First-Quarter 2023 Results; Reaffirms Full-Year 2023 Guidance
RESEARCH TRIANGLE PARK, N.C., April 27, 2023--IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today reported financial results for the quarter ended March 31, 2023.
ZacksIQVIA (IQV) to Report Q1 Earnings: What's in the Cards?
IQVIA's (IQV) first-quarter 2023 revenues are expected to have increased year over year.
- Business Wire
IQVIA Named a Leader in Everest Group Life Sciences Customer Experience Platforms PEAK Matrix® Assessment 2023
RESEARCH TRIANGLE PARK, N.C., April 20, 2023--IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the pharmaceutical and broader life sciences industry, today announces the company has been recognized as a Leader in Customer Experience Platforms (CXP) by Everest Group for its Orchestrated Customer Engagement (OCE) platform.
ZacksHere's Why Investors Should Retain IQVIA Holdings (IQV) Stock
Market size and data reserve are positives for IQVIA Holdings (IQV). Foreign currency risk is bothersome.
- Business Wire
IQVIA to Announce First-Quarter 2023 Results on April 27, 2023
RESEARCH TRIANGLE PARK, N.C., April 06, 2023--IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) will announce its first-quarter 2023 financial results before the market opens on Thursday, April 27, 2023. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com.
Motley Fool2 Clinical Research Stocks That Could Grow by More Than 10% This Year, and 1 to Watch
According to the National Center for Advancing Translational Sciences, the average period from therapy discovery to Food and Drug Administration (FDA) approval is 14 years and costs $1 billion. Clinical research organizations (CROs) and contract development and manufacturing organizations (CDMOs) are growing because the increasing price of developing, testing, manufacturing, and marketing therapies has made it more important that pharmaceutical companies speed the process along with fewer failures. Rather than doing all the clinical trial work or manufacturing work in-house, more healthcare companies are turning to CROs and CDMOs to reduce overhead and expedite bringing therapies to market.
- Business Wire
Global Clinical Trial Activity Remained Resilient in 2022 Despite The Continued Pandemic, Says IQVIA Institute
RESEARCH TRIANGLE PARK, N.C., March 14, 2023--In 2022, global clinical trial activity remained resilient even as the COVID-19 pandemic stretched through the year, with a 1% decline in non-COVID trial activity compared to 2021. COVID-19 trials as a percentage of total trial activity dropped from 10% to 6% of the 5,756 total trials run in 2022. Non-COVID trial activity increased by 8% between 2019 and 2022, suggesting a restoration to pre-pandemic growth rates, according to a new report, Global Tr
- Business Wire
IQVIA CFO Ron Bruehlman to Speak at Barclays Global Healthcare Conference on March 15, 2023
RESEARCH TRIANGLE PARK, N.C., March 01, 2023--IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Barclays Global Healthcare Conference in Miami, FL on Wednesday, March 15, 2023 at 9:30 a.m. ET.
- Business Wire
IQVIA Publishes its 2022 Environmental, Social and Governance Report
RESEARCH TRIANGLE PARK, N.C., February 23, 2023--IQVIA (NYSE:IQV) has published its 2022 Environmental, Social and Governance (ESG) Report. The annual report provides a detailed account of the organization’s focus on reducing its environmental impact and commitment to accelerating positive outcomes for public health and patients.
Motley FoolGot $300? 3 Growth Stocks to Buy That Could Double Your Money
For investors looking to double their money, look for healthcare stocks that are consistently increasing revenue and earnings per share (EPS). Cigna Group (NYSE: CI), Danaher (NYSE: DHR), and IQVIA Holdings (NYSE: IQV) all have managed to generate double-digit (or higher) increases in either quarterly revenue and earnings per share, or both, over the past five years. Let's find out a bit more about these three growth stocks.
ZacksFidelity National (FIS) Q4 Earnings Beat on Banking Business
Fidelity National's (FIS) fourth-quarter results reflect sound contributions from its Banking and Capital Markets businesses. Management announces plan to spin off its Merchant Solutions unit.
- Zacks
IQVIA (IQV) Q4 Earnings and Revenues Beat Mark, Rise Y/Y
IQVIA (IQV) fourth-quarter 2022 earnings and revenues surged year over year.
ZacksIQVIA Holdings (IQV) Beats Q4 Earnings and Revenue Estimates
IQVIA (IQV) delivered earnings and revenue surprises of 1.09% and 0.93%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
